Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Insulet Corporation(PODD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PODD
11/06/2026: PODD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Insulet Corporation is a specialized medical device company known for its Omnipod insulin management system, which provides a tubeless, wearable alternative for diabetes patients. Its main strength lies in its recurring revenue model driven by consumable pods and its differentiated product design. The primary growth opportunity for Insulet involves expanding its user base into the broader type 2 diabetes population and increasing its international footprint. However, the company faces risks from intense competition, reliance on third-party sensor integration, and potential reimbursement pressures. It is generally better suited for growth-oriented investors who are comfortable with the inherent volatility and high valuation associated with specialized medical technology.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a high-growth medical device sub-sector with a strong track record of expanding its addressable market. |
| Momentum investor | Strong fit while signal remains positive | The stock often exhibits strong price trends tied to innovation milestones and earnings surprises in the diabetes market. |
| Value investor | Weak fit | Insulet often trades at a premium valuation reflecting its growth prospects rather than traditional value metrics. |
| Dividend investor | Weak fit | Insulet does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Mixed fit | The high valuation and reliance on a single technology category contribute to inherent market volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is sensitive to growth expectations and competitive news within the diabetes sector. |
| Valuation risk | Medium / high | High growth multiples can lead to significant corrections if quarterly growth targets are missed. |
| Competition risk (Diabetes Technology) | Medium / high | Incumbents like Medtronic and innovators like Tandem constantly release new devices that challenge Insulet's differentiation. |
| Business quality | Strong | The recurring nature of the pod-based model creates a high-quality, sticky revenue stream. |
| Dividend income | Low / none | The company does not provide income through dividends. |
| Execution risk | Medium | The company must consistently execute on manufacturing scale and international regulatory approvals to meet growth targets. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -9.55% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.16B USD | Price to earnings Ratio 23.94 | 1Y Target Price 168.48 |
Price to earnings Ratio 23.94 | 1Y Target Price 168.48 | ||
Volume (30-day avg) 1.6M shares | Beta 1.05 | 52 Weeks Range 126.40 - 354.88 | Updated Date 11/06/2026 |
52 Weeks Range 126.40 - 354.88 | Updated Date 11/06/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.12 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Omnipod Consumables | Recurring revenue from the sale of disposable Omnipod insulin pumps. | This is the primary engine of the company, as it generates consistent, recurring sales from existing users. |
| Personal Diabetes Managers (PDM) | Sales of the controller devices used to manage the pods. | These devices often have lower margins but are essential for gaining new users and locking them into the ecosystem. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 1.59 | Actual 1.99 |
Profitability
Profit Margin 13.44% | Operating Margin (TTM) 22.54% |
Management Effectiveness
Return on Assets (TTM) 11.4% | Return on Equity (TTM) 28.94% |
Valuation
Trailing PE 23.94 | Forward PE 20.2 | Enterprise Value 11.21B | Price to Sales(TTM) 3.19 |
Enterprise Value 11.21B | Price to Sales(TTM) 3.19 | ||
Enterprise Value to Revenue 3.51 | Enterprise Value to EBITDA 15.7 | Shares Outstanding 69.37M | Shares Floating 69.08M |
Shares Outstanding 69.37M | Shares Floating 69.08M | ||
Percent Insiders 0.33 | Percent Institutions 105.48 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.